Akèy › Myelom Miltip › Florid › Tampa
Etid klinik pou Myelom Miltip nan Tampa, FL
15 etid pou Myelom Miltip ap chèche patisipan nan sit nan ak bò kote Tampa (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Ap rekriteFaz 1
- Moffitt Cancer Center /ID# 279068, Tampa
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Ap rekriteFaz 3
- Research Site, Tampa
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 3
- Moffit Cancer center, Tampa
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Ap rekriteFaz 4
- Moffitt Cancer Center, Tampa
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 2
- Moffitt Cancer Center, Tampa
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1/2
- Research Site, Tampa
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Ap rekriteFaz 1/2
- Research Site, Tampa
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Ap rekriteFaz 3
- Research Site, Tampa
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Ap rekriteFaz 1/2
- Moffitt Cancer Center /ID# 272628, Tampa
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Ap rekriteFaz 3
- Moffitt at Memorial Healthcare System, Tampa
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1/2
- Moffitt Cancer Center - McKinley Drive, Tampa
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Ap rekriteFaz 1/2
- Moffitt Cancer Center, Tampa
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
Etid Myelom Miltip nan lòt vil
- New York City, NY60 etid
- Boston, MA42 etid
- Atlanta, GA41 etid
- Houston, TX38 etid
- Durham, NC37 etid
- Nashville, TN32 etid
- Denver, CO27 etid
- Rochester, MN24 etid
- St. Louis, MO24 etid
- Columbus, OH24 etid
- Baldwin Park, CA23 etid
- Chicago, IL22 etid
Lòt etid nan Tampa
- Kansè Poumon ki pa ti selil51 etid
- Kansè nan tete43 etid
- Kansè (tout kalite)39 etid
- Kansè kolorektal33 etid
- Kansè Metastatik29 etid
- Kansè poumon29 etid
- Leksemi mieloïd egi29 etid
- Kansè pankreyas26 etid
- Kansè ovè21 etid
- Sendwòm myelodisplastik19 etid
- Melanom19 etid
- Ensifizyans kadyak18 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.